Agnucastoside C



Compound IDCDAMM01270
Common nameAgnucastoside C
IUPAC name1-[6-[3-(3,4-dihydroxyphenyl)prop-2-enoyloxymethyl]-3,4,5-trihydroxyoxan-2-yl]oxy-6-[3-(4-hydroxyphenyl)prop-2-enoyloxy]-7-methyl-1,4a,5,6,7,7a-hexahydrocyclopenta[c]pyran-4-carboxylic acid
Molecular formulaC34H36O15

Experimental data

Retention time18.71
Adduct[M+Na]+
Actual mz707.196
Theoretical mz707.194
Error2.1
Ionizaton modePositive
Instrument typeLC-MS/MS-QTOF, spectrum predicted by MS-DIAL v4.9 integrated with MS-FINDER 3.60
Score6.0902

Identifiers and class information

Inchi keyWUVKQNIZPPBNHK-YEMXDPAINA-N
SmilesO=C(O)C1=COC(OC2OC(COC(=O)C=CC3=CC=C(O)C(O)=C3)C(O)C(O)C2O)C4C1CC(OC(=O)C=CC5=CC=C(O)C=C5)C4C
SuperclassLipids and lipid-like molecules
ClassPrenol lipids

Pharmacokinetic properties

Number of descriptor values(#stars)9
Number of non-conjugated amine groups (#amine)0
Number of amidine and guanidine groups (#amidine)0
Number of carboxylic acid groups (#acid)1
Number of non-conjugated amide groups (#amide)0
Number of rotatable bonds (#rotor)18
Number of reactive functional groups (#rtvFG)4
Predicted central nervous system activity (CNS)-2
Molecular weight (mol_MW)684.649
Computed dipole moment(dipole)7.538
Total solvent accessible surface area (SASA)1065.23
Hydrophobic component of SASA (FOSA)256.536
Hydrophilic component of SASA (FISA)451.709
Pie component of the SASA (PISA)356.986
Weakly polar component of the SASA (WPSA)0
Total solvent accesible volume (volume)1961.54
Number of hydrogen bond donors (donorHB)7
Number of hydrogen bond acceptors (accptHB)18.45
Free energy of solvation of dipole (dip^2/V)0.0289711
Index of cohesive interaction in solids (ACxDN^.5/SA)0.0458249
Globularity descriptor (glob)0.711409
Predicted polarizability in cubic angstroms (QPpolrz)64.198
Predicted hexadecane/gas partition coefficient (QPlogPC16)24.621
Predicted octanol/gas partition coefficient (QPlogPoct)43.163
Predicted water/gas partition coefficient (QPlogPw)32.238
Predicted octanol/water partition coefficient (QPlogPo/w)0.848
Predicted aqueous solubility (QPlogS)-5.582
Conformation-independent predicted aqueous solubility (CIQPlogS)-6.268
Predicted IC50 value for blockage of HERG K+ channels (QPlogHERG)-6.097
Predicted apparent Caco-2 cell permeability in nm/sec (QPPCaco)0.131
Predicted brain/blood partition coefficient (QPlogBB)-6.472
Predicted apparent MDCK cell permeability in nm/sec (QPPMDCK)0.04
Predicted skin permeability, log Kp (QPlogKp)-6.859
PM3 calculated ionization potential (IP(ev))8.938
PM3 calculated electron affinity (EA(eV))0.845
Number of likely metabolic reactions (#metab)7
Prediction of binding to human serum albumin (QPlogKhsa)-0.854
Predicted qualitative human oral absorption (HumanOralAbsorption)1
Predicted human oral absorption on 0 to 100% scale (PercentHumanOralAbsorption)0
Solvent-accessible surface area of fluorine atoms (SAFluorine)0
Solvent-accessible surface area of amide oxygen atoms (SAamideO)0
Van der Waals surface area (PSA)268.02
Number of nitrogen and oxygen atoms (#NandO)15
Number of violations of Lipinski’s rule of five (RuleOfFive)3
Number of violations of Jorgensen’s rule of three (RuleOfThree)2

Compound-target network

Cytoscape Graph

Protein targets associated with phytocompound

Uniprot ID Gene name Target name TTD_ID Prediction source
P02766TTRTransthyretinT86462SEA
P43166CA7Carbonic anhydrase VIIT37541SEA
P23280CA6Carbonic anhydrase VIT06569SEA
Q9ULX7CA14Carbonic anhydrase XIVT31992SEA
P15121AKR1B1Aldose reductaseT26623SEA
P60568IL2Interleukin-2T61698SEA
Q9NUW8TDP1Tyrosyl-DNA phosphodiesterase 1T33492SEA
P14679TYRTyrosinaseT97035SEA
Q9GZQ4NMUR2Neuromedin-U receptor 2T04210SEA
O43826SLC37A4Glucose-6-phosphate translocaseT47306SEA

Target associated diseases

TTD_ID Disease_ID Disease name ICD_11 Uniprot ID Gene names
T86462DI0026Amyloidosis[ICD-11: 5D00]P02766TTR
T06569DI0046Bacterial infection[ICD-11: 1A00-1C4Z]P23280CA6
T06569DI0372Seborrhoeic dermatitis[ICD-11: EA81]P23280CA6
T31992DI0046Bacterial infection[ICD-11: 1A00-1C4Z]Q9ULX7CA14
T31992DI0204Inborn metabolism deficiency[ICD-11: 5C50-5C59]Q9ULX7CA14
T26623DI0298Neuropathy[ICD-11: 8C0Z]P15121AKR1B1
T26623DI0366Rheumatoid arthritis[ICD-11: FA20]P15121AKR1B1
T61698DI0275Multiple sclerosis[ICD-11: 8A40]P60568IL2
T61698DI0361Renal cell carcinoma[ICD-11: 2C90]P60568IL2
T97035DI0007Acquired hypermelanosis[ICD-11: ED60]P14679TYR
T97035DI0008Acquired hypomelanotic disorder[ICD-11: ED63]P14679TYR

Copyright © 2025